Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.
about
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
P2860
Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Indirect treatment comparison ...... renal cell carcinoma therapy.
@ast
Indirect treatment comparison ...... renal cell carcinoma therapy.
@en
type
label
Indirect treatment comparison ...... renal cell carcinoma therapy.
@ast
Indirect treatment comparison ...... renal cell carcinoma therapy.
@en
prefLabel
Indirect treatment comparison ...... renal cell carcinoma therapy.
@ast
Indirect treatment comparison ...... renal cell carcinoma therapy.
@en
P2093
P2860
P356
P1476
Indirect treatment comparison ...... c renal cell carcinoma therapy
@en
P2093
Bernard Escudier
Björn Schwander
Gerald Hj Mickisch
Joaquim Bellmunt
José P Maroto
Stefan Walzer
P2860
P356
10.2147/CEOR.S16118
P407
P577
2011-01-25T00:00:00Z